Equillium (EQ) Total Non-Current Liabilities (2017 - 2021)
Equillium (EQ) reported Total Non-Current Liabilities of $16.7 million for Q3 2021, up 17.36% year-over-year from $14.2 million in Q3 2020, and up 10.66% on a QoQ basis from $15.0 million in Q2 2021.
Equillium (EQ) has 5 years of Total Non-Current Liabilities data on file, last reported at $16.7 million in Q3 2021.
- Quarterly Total Non-Current Liabilities rose 17.36% year-over-year to $16.7 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $16.7 million (up 17.36% YoY) and the FY2020 annual result came in at $15.5 million, up 14.42% from the prior year.
- Total Non-Current Liabilities advanced to $16.7 million in Q3 2021 per EQ's latest filing, from $15.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $16.7 million in Q3 2018 and bottomed at $163000.0 in Q2 2019.
- The 5-year median for Total Non-Current Liabilities is $13.7 million (2019), against an average of $11.2 million.
- The widest annual swing landed in 2018, when Total Non-Current Liabilities tumbled 97.68%; it then jumped 7996.32% in 2020.
- Tracing EQ's Total Non-Current Liabilities over 5 years: stood at $8.6 million in 2017, then plunged by 97.68% to $200000.0 in 2018, then jumped by 6682.0% to $13.6 million in 2019, then increased by 14.42% to $15.5 million in 2020, then gained by 7.29% to $16.7 million in 2021.
- Per Business Quant, the three latest EQ Total Non-Current Liabilities figures stand at $16.7 million (Q3 2021), $15.0 million (Q2 2021), and $14.9 million (Q1 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Equillium | 279.21 Mn | 218.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 16.65 Mn |
| Jun 30, 2021 | 15.05 Mn |
| Mar 31, 2021 | 14.92 Mn |
| Dec 31, 2020 | 15.52 Mn |
| Sep 30, 2020 | 14.19 Mn |
| Jun 30, 2020 | 13.20 Mn |
| Mar 31, 2020 | 13.46 Mn |
| Dec 31, 2019 | 13.56 Mn |
| Sep 30, 2019 | 13.89 Mn |
| Jun 30, 2019 | 163,000.00 |
| Mar 31, 2019 | 181,000.00 |
| Dec 31, 2018 | 200,000.00 |
| Sep 30, 2018 | 16.65 Mn |
| Dec 31, 2017 | 8.63 Mn |